Schizophrenia — Comprehensive Study Materials Summary & Study Notes

🧠 Overview

Schizophrenia is a chronic psychiatric disorder characterized by recurrent or persistent psychosis and functional impairment. It affects roughly 0.28–0.6% of the population, often emerges earlier in men, and is associated with high rates of comorbidity and reduced life expectancy.

📊 Epidemiology & Risk Factors

Common risk factors include genetic predisposition (first-degree relatives ≈10% risk), obstetric complications (e.g., neonatal hypoxia), childhood trauma, cannabis use, and urban upbringing. Comorbid conditions frequently include anxiety, depression, substance use, metabolic and neurological problems.

🧬 Pathophysiology Hypotheses

Multiple neurotransmitter theories contribute: the dopamine hypothesis (excess mesolimbic dopamine → positive symptoms; reduced mesocortical dopamine → negative/cognitive symptoms), the glutamate hypothesis (NMDA receptor hypofunction), and the serotonin hypothesis (5-HT2A modulation of dopaminergic pathways). These models inform pharmacologic targets.

🔍 Clinical Presentation

Symptoms typically evolve through a prodromal phase (adolescence) to overt psychosis (adulthood). Core domains are positive symptoms (hallucinations, delusions, disorganized speech/behavior), negative symptoms (apathy, social withdrawal, paucity of speech), and cognitive impairments (processing speed, memory, executive function). Mood and anxiety symptoms are common; neurologic and metabolic disturbances are often medication-related.

🧾 Diagnosis (DSM-V Essentials)

Diagnosis relies on clinical assessment and exclusion of other causes. DSM-V requires at least two core symptoms (delusions, hallucinations, disorganized speech, grossly disorganized/catatonic behavior, negative symptoms) for a significant portion of 1 month, with continuous signs for at least 6 months and associated social/occupational dysfunction.

⚠️ Differential: Medication- and Substance-Induced Psychosis

Always exclude drug-induced causes (e.g., stimulants, hallucinogens, anticholinergics, steroids, some antibiotics/anticonvulsants) and intoxication/withdrawal states before confirming primary schizophrenia.

💊 Treatment Principles

Management is multimodal: antipsychotic pharmacotherapy is first-line for positive symptoms, combined with psychosocial interventions (CBT, psychoeducation, supported employment). Goals are symptom reduction, relapse prevention, functional recovery, and minimizing adverse effects.

🧾 Antipsychotic Classes & Selection

Two broad classes: first-generation antipsychotics (FGAs) — strong D2 antagonists (higher EPS/tardive dyskinesia risk), and second-generation antipsychotics (SGAs) — combined D2 and 5-HT2A antagonism (lower EPS, more metabolic risk). Drug choice depends on prior response, side-effect vulnerability, comorbidities, cost, formulation (oral vs LAI), and patient preference.

🔬 Key Drugs — Clinical Points

Risperidone/paliperidone: effective but higher risk of EPS and hyperprolactinemia at higher doses. Olanzapine: strong metabolic risk; metabolism via CYP1A2 — smoking reduces levels. Quetiapine: sedating (H1) and orthostatic hypotension (α1). Ziprasidone: must be taken with food and has mild QT risk but favorable metabolic profile. Aripiprazole/brexpiprazole/cariprazine: partial D2 agonists with lower prolactin and metabolic effects; cariprazine has D3 activity helpful for negative symptoms. Clozapine: most effective for treatment-resistant illness and suicidality but requires strict hematologic and cardiovascular monitoring.

🚨 Clozapine: Monitoring & Use

Reserved for treatment-resistant schizophrenia or suicidality after failed trials of ≥2 antipsychotics. Mandatory baseline and ongoing monitoring includes CBC/ANC (weekly for first 6 months), metabolic labs, ECG, and vigilance for myocarditis (CRP/troponin during early therapy). Start low and titrate; therapeutic plasma concentrations guide dosing in some settings.

🏥 Acute, First-Episode, and Relapse Management

Acute/agitated patients may require short-acting IM antipsychotics (haloperidol, olanzapine, aripiprazole, ziprasidone) and careful safety planning. First-episode patients are more sensitive to adverse effects; SGAs (olanzapine, risperidone, quetiapine) are often preferred at limited doses. For relapse, assess adherence, stressors, and substance use; titrate or switch antipsychotics as indicated.

🔁 Maintenance & Long-Acting Injectables (LAIs)

Maintenance aims to minimize symptoms and prevent relapse while using the lowest effective dose. LAIs improve adherence and are indicated for patients with recurrent relapses due to nonadherence; they are not ideal for initial acute management due to slow attainment of steady state.

⚕️ Management of Common Adverse Effects

EPS (parkinsonism, dystonia, akathisia): manage with dose reduction, anticholinergics, benzodiazepines, or β-blockers (for akathisia). Tardive dyskinesia: consider switching to clozapine/quetiapine and symptomatic options. Metabolic effects: choose lower-risk agents, lifestyle interventions, and treat with metformin when indicated. Recognize and treat neuroleptic malignant syndrome (NMS) emergently (withdraw antipsychotic, supportive care, dantrolene/bromocriptine).

🔄 Switching & Treatment-Resistant Criteria

Allow 2–8 weeks at therapeutic doses to judge response; treatment-resistant schizophrenia typically defined by inadequate response to ≥2 antipsychotics of different classes, given at adequate dose and duration (≥6 weeks). Clozapine is the evidence-based next step for TR schizophrenia.

🤰 Pregnancy & Breastfeeding Considerations

Most women with established illness should continue treatment using the lowest effective dose; avoid initiating depot formulations in pregnancy if possible. Olanzapine and clozapine carry higher risks for large-for-gestational-age infants and need gestational diabetes screening; clozapine is generally avoided during breastfeeding.

🧑‍⚕️ Role of the Pharmacist

Pharmacists educate patients and families, simplify regimens, coordinate care, ensure optimal dosing, monitor for interactions and adverse effects, and assist in selecting agents to minimize harm while preserving efficacy.

✅ Takeaway Points

Schizophrenia is heterogeneous and requires individualized pharmacologic and psychosocial strategies. Positive symptoms respond well to antipsychotics; negative and cognitive deficits are harder to treat. Safe use of antipsychotics requires attention to side-effect profiles, monitoring needs (especially for clozapine), and support for adherence (including LAIs).